BioMarin Pharmaceuticals
BMRN
316 hedge funds and large institutions have $10.7B invested in BioMarin Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 110 increasing their positions, 123 reducing their positions, and 35 closing their positions.
154% more call options, than puts
Call options by funds: $86.2M | Put options by funds: $34M
19% more capital invested
Capital invested by funds: $8.94B → $10.7B (+$1.73B)
0% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 35
2% less funds holding
Funds holding: 321 → 316 (-5)
11% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 123
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$221M |
| 2 |
O
OppenheimerFunds
New York
|
+$88.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$41.7M |
| 4 |
Jennison Associates
New York
|
+$40.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$89.3M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$73.4M |
| 3 |
JCP
Jabre Capital Partners
Geneva,
Switzerland
|
-$48.1M |
| 4 |
Neuberger Berman Group
New York
|
-$46.5M |
| 5 |
HCM
Holland Capital Management
Chicago,
Illinois
|
-$46.2M |
BMRN Hedge Fund Activity: Q3 2014 in Review
316 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2014, worth a combined $10.7B — up 19% from $8.94B a quarter earlier.
Fund positioning in BMRN was balanced in Q3 2014: 35 funds opened new positions, 35 closed out, 110 added to existing stakes and 123 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $221M. The largest seller was OrbiMed, exiting entirely with an estimated $89.3M sold.
- 316 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2014, down from 321 in Q2 2014.
- Funds reported $10.7B of BioMarin Pharmaceuticals stock for Q3 2014, up 19% quarter-over-quarter.
- 35 funds opened new BioMarin Pharmaceuticals positions in Q3 2014 and 35 closed out, a net change of 0 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2014 was Fidelity Investments, an estimated $221M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2014 was OrbiMed, an estimated $89.3M sold.
Based on aggregated 13F filings for Q3 2014.